Search
forLearn
5 / 801 resultslearn Sodium PCA
learn nicotinamide
learn NMN
learn ORPL
Research
5 / 9 results
research Revised NPRT Classification System Encompasses Additional Patterns of Male and Female Hair Loss
The updated NPRT system now covers different types of hair loss in men and women.
research How I Do It: Ahmad’s NPRT System: A New Classification System for Documenting Male Pattern Baldness
Dr. Muhammad Ahmad created a simpler system to better describe male pattern hair loss.
research Evaluation of Five Hundred Patients using Ahmad’s NPRT System for Documenting Male Pattern Baldness
Ahmad's NPRT system accurately documents and predicts male pattern baldness.
research Clinical experience on follicular unit extraction megasession for severe androgenetic alopecia
FUE megasession effectively treats severe hair loss with natural-looking results in one operation.
research Analysis of the changes in scalp hair angles: In vivo and in vitro comparison before and after tumescence
Tumescent fluid increases scalp hair angles, which may improve hair transplant results and reduce surgeon fatigue.
Community Join
5 / 1000+ resultscommunity Will Pelage include Norwood 7 hair loss in PP405 phase 3 trials to see its true regenerative potential?
Norwood 7 hair loss is often excluded from trials to ensure treatments appear more effective and to reduce costs. Some believe treatments effective for Norwood 5 could work on Norwood 7, but companies prioritize market readiness.
community Hair loss treatments rated (by gpt-4)
Rating treatments for hair loss, with the help of GPT-4, according to efficacy, evidence and tolerability; a combination of chemicals from research papers, custom compounds, and some suggestions from other users were included.
community Anagenic is trying to compound Gt20029
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community A warning to anyone considering 3rd party sourcing PP405 or its analogs
Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.